ImmuPharma (LON:IMM) Shares Up 28.6% - Here's Why

Key Points

• ImmuPharma's shares surged by 28.6% on Tuesday, trading as high as GBX 11.99 after closing at GBX 8.79 the previous day.
• The trading volume increased significantly, with 16.6 million shares exchanged, a 92% rise from the average session volume.
• ImmuPharma specializes in peptide-based therapeutics, focusing on autoimmune diseases and has a lead program targeting the treatment of Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) shot up 28.6% on Tuesday . The stock traded as high as GBX 11.99 ($0.16) and last traded at GBX 11.30 ($0.15). 16,577,539 shares were traded during trading, an increase of 92% from the average session volume of 8,612,375 shares. The stock had previously closed at GBX 8.79 ($0.12).

ImmuPharma Trading Up 28.6%

The firm has a market cap of £56.47 million, a price-to-earnings ratio of -1,269.66 and a beta of 1.53. The firm has a 50-day moving average of GBX 5.30 and a two-hundred day moving average of GBX 3.58.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, equities analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.